ALSO NOTED: US Oncology's CFO retires; Profits rise at Novartis, Merck, Lilly; and much more...

> US Oncology's CFO Rick McCook is resigning to explore opportunities in a retail or manufacturing business. Release

> Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from one-time gains. But increases are always better than the alternative. Report

> Seeking Alpha profiles Synta's metastatic melanoma therapy Elesclomol. Report

> Last week, we reported on Big Pharma's march on the capital in support of new off-label marketing rules. Now, opponents of those rules are drawing on another of last week's news events for support: the Vioxx ghostwriting story. Report

> A Roche distributor tattled to India's Drug Controller General, accusing Cipla of promoting its generic version of a Roche drug for an unapproved use. Report

And Finally... Higher food prices and grain shortages are changing attitudes toward biotech crops. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.